An interventional study of LSG and CMT in Type 2 Diabetes Mellitus, sponsored by Azienda Ospedaliera Santa Maria, Terni, Italy. Completed at 2 sites in Italy. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Azienda Ospedaliera Santa Maria, Terni, Italy · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.
Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 297th largest by enrollment of the 321 interventional ones that give a count, is one of 24 that started in 2015, is one of 71 with no phase, and was the 216th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Italy, United States, Argentina and 13 more countries
Ages 45+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Italy, United States, Argentina and 12 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Brazil and 8 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
421 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 44 · Phase 3 157 · Phase 4 54
First in 1997; this study’s year is marked. 24 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 320 across the 321 interventional studies, 500 across the 99 observational. Of the 317 that completed or were terminated, 132 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
227 of 421 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliera Santa Maria, Terni, Italy is the lead sponsor of 2 studies on the registry; none are open to participants now.
Azienda Ospedaliera Santa Maria, Terni, Italy has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetes Mellitus, Type 2 with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07149610Marche Region Regional Health AgencyConnected Care for Type 2 Diabetes Self-Management | 2026-11-30 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07783893Marche Region Regional Health AgencyE-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy | 2026-12 |
| NCT05759637Istituto Auxologico ItalianoType 2 Diabetes, Obesity and Cortisol Excess | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bariatric surgery is efficient in both inducing adequate weight loss and the control of glycemia in obese patients affected by Type 2 Diabetes Mellitus (T2DM).
Despite growing evidence suggesting that early performance of bariatric surgery on obese patients with T2DM offers the best opportunity to reach and maintain a remission of diabetes, no randomized clinical trials (RCT) have evaluated its efficiency in patients with new T2DM diagnosis.
The aim of this RCT is to compare bariatric surgery, and in particular Laparoscopic Sleeve Gastrectomy (LSG), with conventional medical therapy (CMT) in patients with new T2DM diagnosis that are obese (Body Mass Index, BMI of between 30 and 42 Kg/m2), to be recruited at two Italian diabetology centres (Terni and Rome).
The main objective of the present RCT is to investigate the efficacy of LSG as compared with CMT in inducing and maintaining both a resolution of T2DM (defined as HbA1c levels ≤6.0%, without active pharmacologic therapy or ongoing procedures) and the remission of T2DM through the evaluation of the criteria provided by the American Diabetes Association (ADA) at maximum follow-up of 6 years. The effects of the two treatments in terms of weight loss and the quality of life of the patient will also be taken into consideration.
Any positive results of this study will include preventing microvascular and macrovascular complications connected with diabetes, without the necessity to take medication, and at the same time the loss of excess body weight and improved quality of life (QOL).
Recent evidence suggests that, in obese patients with type 2 diabetes mellitus of long duration, and / or poorly controlled with conventional therapy, bariatric surgery promises diabetes remission rates significantly higher than those attainable with traditional treatment, irrespective of initial BMI and the loss of body weight of the patients.
This has ensured the growing conviction in the international scientific community that bariatric surgery should not be considered as an alternative to conventional obesity and diabetes therapies only after the failure of traditional treatments, but should be performed with the intent to prevent complications associated with these diseases, and therefore at their onset [23]. Furthermore, the use of BMI as the main parameter to guide the indication of bariatric surgery is increasingly being called into question with regard to the presence of comorbidities such as diabetes, as it is the distribution of obesity, together with the presence of comorbidities such as diabetes, rather than the degree of obesity that predicts the onset of related complications.
Bariatric surgery is currently regarded as a "last resort" for both the treatment of obesity and its associated comorbidities, such as diabetes, particularly in patients with a BMI ≤ 35. Despite this, it is now apparent that initial BMI and body weight loss resulting from bariatric surgery have no connection with the metabolic effects of the procedure, such as on the treatment of diabetes. In fact, according to the current national and international guidelines (which are based on a consensus dated 1991[6]), bariatric surgery may be considered in diabetic patients, with a BMI between 30 and 39.9 Kg/m2, only after the recorded failure of conventional medical therapies for obesity and diabetes.
This wait-and-see policy is due to the fact that bariatric surgery is a surgical procedure that is associated, depending on the procedure, with a certain rate of short and long term potential adverse events, and while in the short-medium term it has been shown to achieve significantly higher rates of remission from diabetes, when compared to medical therapy, there remain uncertainties about the durability of remission of diabetes and weight control after long follow-up periods. Essentially, therefore, the risk-benefit ratio has not allowed for the use of bariatric surgery as a first-line therapy for the treatment of type 2 diabetes in obese patients, and in particular in class 1 and 2 obesity. It can be hypothesized, however, that the performance of LSG at diagnosis of diabetes in obese patients can dramatically improve both the resolution/remission rate and the duration of resolution/remission from diabetes, and thus improve the protection against the development of vascular complications.
In fact, growing evidence suggests that the period of time between the diagnosis of diabetes and bariatric surgery is a determining factor in the achievement and duration of diabetes remission. It has also been observed that bariatric surgery is more effective than medical therapy in preventing diabetes in obese patients.
In the opinion of the authors, the early performance of LSG, also at the diagnosis of diabetes, could be crucial. This is hypothesized also on the basis of the well-known phenomenon of "glycemic legacy", according to which the greater the time elapsed between diabetes diagnosis and the achievement, with any form of therapy, of glycemic control targets, the lower the benefit in terms of protection from the development of vascular complications associated with diabetes [34]. It follows that blood glucose control in patients with newly diagnosed diabetes should be achieved through the implementation of appropriate treatments, including bariatric surgery, as quickly as possible after diagnosis. In this sense, bariatric surgery (and in particular, LSG) has been proven capable of promoting glycemic control in the short to medium term, in terms of the substantial and rapid reduction of glycated haemoglobin, (even 3 months after surgery), compared to conventional medical therapy in patients with longstanding diabetes (about 9 years on average). In the RCT conducted by Schauer et al., 3 months after sleeve gastrectomy, average HbA1c levels were reduced from an initial average value of 9.5% to 7%, while in the medical-therapy group they were reduced from an initial value of 8.9% to 7.7%,therefore significantly less effective than LSG. Thus irrespective of the rate of achievement and duration of eventual remission of diabetes (that in any case is already at present considerably higher than medical therapy in patients with longstanding and poorly controlled diabetes), patients undergoing sleeve gastrectomy (and bariatric surgery in general) could benefit from the procedure being performed on diagnosis of diabetes, and therefore as soon as possible, thanks to the ability to reach the HbA1c target level for glycemic control more easily and quickly than with medical therapy. This would have a proven protective effect on long-term vascular complications, irrespective of the duration of the glycemic control and the achievement of any remission on the basis of the concept of "glycemic legacy" and "metabolic memory" , through the analysis of the results of the largest and most prestigious international randomized clinical trials on the treatment of diabetes (UKPDS, DCCT/EDIC, ACCORD and VATD trials).
The phenomenon of metabolic memory refers to the fact that the UKPDS and DCCT / EDIC studies have demonstrated that even a transitory period of aggressive glycemic control, such as that attainable after bariatric surgery, is capable of inducing a beneficial "metabolic memory", with the effect of reducing microvascular complications over time, regardless of subsequent maintenance of glycemic control [32].
Then the rationale for the use of bariatric surgery at diagnosis of type 2 diabetes mellitus is based not only on the hypothesis of the attainment of early and sustained glycemic control in obese patients, but also on a variety of scientific evidence that suggests that the precocity of its performance is a positive predictor of remission and of the long-term maintenance of diabetes remission.
As previously mentioned, the superiority of bariatric surgery to conventional medical therapy in obese patients (even with BMI less than 30) with diabetes of long duration, and / or poorly controlled with conventional therapy, in terms of attaining glycemic control, has clearly been demonstrated , even if for medium-short follow-up periods [1]. When applied in obese patients with new onset diabetes it might therefore subvert the risk-benefit ratio that now prevents its use as a first-line therapy, thanks to an increase in the rate of remission of diabetes and its endurance, as well as a reduction of the long-term vascular complications of diabetes.
In conclusion, a recent American Society of Metabolic and Bariatric Surgery (ASMBS) position statement noted that that class 1 obesity requires effective treatment, as it represents a significant health problem, and that treatment should involve the use of bariatric surgery. Indeed, recent randomized studies have demonstrated both the effectiveness, in terms of weight loss and control of comorbidity, and the safety of some bariatric surgical procedures, including sleeve gastrectomy, in this specific group of patients (Class 1 Obesity).
These observations suggest that T2DM could be treated with bariatric surgery as early as possible, also at the time of diagnosis.
It can be hypothesized that performing LSG at T2DM diagnosis can offer the maximum benefits in terms of both the attainment and duration of T2DM resolution/remission, with the potential to thus prevent micro and macrovascular complications without the need to take medication. Other positive aspects include the possibility to achieve appropriate weight loss and a related improvement in the quality of life. In this randomized trial LSG will be compared with conventional medical therapy in the treatment of T2DM at onset in obese patients with a BMI of between 30 and 42 Kg/m2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
Procedure: LSG · Drug: CMT
CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
Drug: CMT
In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
Rate of patients achieving diabetes resolution
HbA1c levels ≤6.0%, without active pharmacologic therapy or ongoing procedures
Time frame: Assessed up to 1 year after randomization
Rate of patients achieving diabetes resolution
diabetes resolution
Time frame: assessed at 2, 3, 4, 5 and 6 years after randomization
Rate of patients achieving diabetes complete remission (American Diabetes Association criteria)
diabetes complete remission
Time frame: assessed at 2, 3, 4, 5, and 6 years after randomization
Rate of patients achieving HbA1c levels ≤6.5%,
achieving HbA1c levels ≤6.5%,
Time frame: assessed at 1, 2, 3, 4, 5,and 6 years after randomization
Rate of patients achieving HbA1c levels ≤6.5%,
achieving HbA1c levels ≤6.5%,
Time frame: assessed up at 1, 2, 3, 4, 5,and 6 years after randomization
Rate of patients achieving prolonged remission (American Diabetes Association criteria)
achieving prolonged remission
Time frame: Assessed up at 6 years after randomization
Time to achievement (in days) of complete remission
complete remission
Time frame: Assessed up at 2 years after randomization
Time to achievement (in days) of prolonged remission
prolonged remission
Time frame: Assessed up at 6 years after randomization
Total duration of the period with diabetes resolution
diabetes resolution
Time frame: Assessed at 3 and 6 years
Total duration of the period in complete remission
complete remission
Time frame: Assessed at 3 and 6 years
Total duration of the time period with HbA1c ≤ 6.0% irrespective of any active pharmacologic therapy or ongoing procedures
Total duration of the time period with HbA1c ≤ 6.0% irrespective of any active
Time frame: Assessed at 3 and 6 years
Total duration of the period with HbA1c levels ≤6.5%, without active pharmacologic therapy or ongoing procedures
Total duration of the period with HbA1c levels ≤6.5%, without active pharmacologic
Time frame: Assessed at 3 and 6 years
Total duration of the period with HbA1c levels ≤6.5% irrespective of any active pharmacologic therapy or ongoing procedures
Total duration of the period with HbA1c levels ≤6.5% irrespective of any active
Time frame: Assessed at 3 and 6 years
Average value and changes from baseline, during the follow-up period, until the predefined time end-points of anthropometric, blood, urinary and QoL parameters.
Average value and changes from baseline, during the follow-up period, until the
Time frame: Assessed up at 6 years after randomization
Rate of patients with effective weight loss (defined as % Excess Weight Loss > 50%)
Rate of patients with effective weight loss (defined as % Excess Weight Loss \> 50%)
Time frame: Assessed at 2 ,4, 6 years after randomization
Rate of patients with hypertension and / or requiring antihypertensive therapy
Rate of patients with hypertension and / or requiring antihypertensive therapy
Time frame: Assessed at 2,4, 6 years after randomization
Rate of patients with dyslipidemia and / or that require drug therapy for dyslipidemia
Rate of patients with dyslipidemia and / or that require drug therapy for dyslipidemia
Time frame: Assessed at 2,4 6 years after randomization
Complications related to diabetes, or its pharmacological treatment, as well as those resulting from bariatric surgery.
Complications related to diabetes, or its pharmacological treatment, as well as those
Time frame: Assessed at 2,4 6 years after randomization
Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy
Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy
Time frame: Assessed at 2,4, 6 years after randomization
Plan to share: Undecided
The record gives a start of Dec 2015, a primary completion of Jun 2023 and a completion of Jun 2023. It does not say whether these dates are actual or estimated.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2028 → Jun 2023 and completion Mar 2028 → Jun 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliera Santa Maria, Terni, Italy